JP2023553390A5 - - Google Patents

Info

Publication number
JP2023553390A5
JP2023553390A5 JP2023533391A JP2023533391A JP2023553390A5 JP 2023553390 A5 JP2023553390 A5 JP 2023553390A5 JP 2023533391 A JP2023533391 A JP 2023533391A JP 2023533391 A JP2023533391 A JP 2023533391A JP 2023553390 A5 JP2023553390 A5 JP 2023553390A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
car
immune cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023533391A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023553390A (ja
JP7871261B2 (ja
Filing date
Publication date
Priority claimed from US17/476,661 external-priority patent/US11498973B2/en
Application filed filed Critical
Priority claimed from PCT/US2021/061410 external-priority patent/WO2022119923A1/en
Publication of JP2023553390A publication Critical patent/JP2023553390A/ja
Publication of JP2023553390A5 publication Critical patent/JP2023553390A5/ja
Application granted granted Critical
Publication of JP7871261B2 publication Critical patent/JP7871261B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023533391A 2020-12-02 2021-12-01 Bcma標的化キメラ抗原受容体 Active JP7871261B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063120692P 2020-12-02 2020-12-02
US63/120,692 2020-12-02
US202163153666P 2021-02-25 2021-02-25
US63/153,666 2021-02-25
US202163212289P 2021-06-18 2021-06-18
US63/212,289 2021-06-18
US17/476,661 US11498973B2 (en) 2018-04-12 2021-09-16 BCMA-targeted chimeric antigen receptor as well as preparation method therefor and application thereof
US17/476,661 2021-09-16
PCT/US2021/061410 WO2022119923A1 (en) 2020-12-02 2021-12-01 Bcma-targeted chimeric antigen receptors

Publications (3)

Publication Number Publication Date
JP2023553390A JP2023553390A (ja) 2023-12-21
JP2023553390A5 true JP2023553390A5 (cg-RX-API-DMAC7.html) 2024-02-22
JP7871261B2 JP7871261B2 (ja) 2026-06-08

Family

ID=81853652

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023533391A Active JP7871261B2 (ja) 2020-12-02 2021-12-01 Bcma標的化キメラ抗原受容体

Country Status (7)

Country Link
EP (1) EP4255936A4 (cg-RX-API-DMAC7.html)
JP (1) JP7871261B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230117367A (cg-RX-API-DMAC7.html)
CN (1) CN116997345A (cg-RX-API-DMAC7.html)
AU (1) AU2021393434A1 (cg-RX-API-DMAC7.html)
CA (1) CA3201008A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022119923A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20260290A1 (es) 2023-03-31 2026-02-10 Abelzeta Inc Receptores de antigeno quimericos biespecificos dirigidos a cd20 y bcma
KR102869233B1 (ko) * 2024-01-24 2025-10-15 주식회사 박셀바이오 Bcma 특이적 키메라 항원 수용체를 포함하는 신규한 골수 침윤 림프구 집단 및 이의 제조방법
WO2025171388A1 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens with modified domains and related methods and uses
WO2025171383A2 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens and related methods and uses
WO2026006767A1 (en) 2024-06-28 2026-01-02 Dispatch Biotherapeutics, Inc. Tethered il-9/il-9r and related engineered cells and methods
CN119119274B (zh) * 2024-09-26 2026-08-11 北京昌盛鸿途生物科技有限公司 一种靶向bcma的cart细胞及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013246443B2 (en) * 2012-04-11 2017-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting B-cell maturation antigen
MX2019005277A (es) * 2016-11-04 2019-09-27 Bluebird Bio Inc Composiciones de celulas t con car anti-bcma.
ES2968880T3 (es) * 2018-02-01 2024-05-14 Nanjing Iaso Biotechnology Co Ltd Receptor de antígeno quimérico (CAR) que se une a BCMA, y usos del mismo
CN116836297A (zh) * 2018-04-12 2023-10-03 上海赛比曼生物科技有限公司 靶向bcma的嵌合抗原受体及其制法和应用
JP7599205B2 (ja) * 2018-06-01 2024-12-13 アンヘレス セラピューティクス インコーポレイテッド 細胞療法のための多様な抗原結合ドメイン、新規プラットフォームおよびその他の強化
MX2021001083A (es) * 2018-07-31 2021-03-31 Amgen Res Munich Gmbh Regimen posologico para anticuerpos biespecificos contra bcma-cd3.
CN111171158B (zh) * 2020-01-17 2020-10-30 南京蓝盾生物科技有限公司 同时靶向bcma和cd38的嵌合抗原受体及其应用

Similar Documents

Publication Publication Date Title
US12129309B2 (en) Heterodimeric antibodies that bind CD3 and CD38
IL317912A (en) A combined chimeric antigen receptor targeting CD19 and CD20 and its applications
JP7646361B2 (ja) 抗pvrig/抗tigit二重特異性抗体および使用方法
JP2025032091A5 (cg-RX-API-DMAC7.html)
JP2023525778A5 (cg-RX-API-DMAC7.html)
JP2020010699A5 (cg-RX-API-DMAC7.html)
JP2017522879A5 (cg-RX-API-DMAC7.html)
JP2020529970A5 (cg-RX-API-DMAC7.html)
US20230121135A1 (en) Compositions and methods for targeting cd33-expressing cancers
CN107660214A (zh) 针对cd3和cd20的双特异性抗体
JP2024527557A5 (cg-RX-API-DMAC7.html)
JP2024534847A5 (cg-RX-API-DMAC7.html)
IL304857A (en) Preparations and methods for treating HER2 POSITIVE cancer
CN121511254A (zh) 抗cd28组合物
EP4676519A1 (en) Combination therapy of an anti-egfrviii/anti-cd3 antibody and an tumor-targeted 4-1bb agonist
JP2025505933A5 (cg-RX-API-DMAC7.html)
JP2022546590A5 (cg-RX-API-DMAC7.html)
KR20240155275A (ko) 항 글루코코르티코이드 유도 tnfr 관련(gitr) 단백질 항체 및 이의 용도
NZ768183B2 (en) Humanized bcma antibody and bcma-car-t cells
AU2021410416A1 (en) Polypeptide specific for mucin 1 and use thereof
RU2019123366A (ru) Антитело, нацеленное на всма, и его применение
HK1261817B (en) Heterodimeric antibodies that bind cd3 and cd38
HK1261817A1 (en) Heterodimeric antibodies that bind cd3 and cd38